Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$-188.0K-108.07%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Marianne De Backer
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 367
- Beta
- 1.70
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 2.44
Financials
Revenue
$-188.0K-108.1%Net Income
$-96.25MEBITDA
$-96.39MFree Cash Flow
$-106.11MEPS (diluted)
$-0.57Shares Outstanding (diluted)
169.28M+2327.4%Operating Expenses
$104.47MCash & Debt
$458.36MRevenue by Segment (annual)
$68.56MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $68.56M | $-437.99M | $-3.16 |
| 2024 | $74.20M | $-521.96M | $-3.83 |
| 2023 | $86.18M | $-615.06M | $-4.59 |
| 2022 | $1.62B | $515.84M | $3.89 |
| 2021 | $1.10B | $528.58M | $4.07 |
| 2020 | $76.37M | $-298.67M | $-2.51 |
| 2019 | $8.09M | $-174.68M | $-1.62 |
| 2018 | $10.67M | $-115.88M | $-1.20 |
| 2017 | $2.71M | $-69.85M | $-10.02 |
Valuation
VIRhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
153+206.67%Social Signal Score
Mentions (11)
- Newsmarketbeat.com·12d ago·Neutral
Vir Biotechnology Hepatitis Delta Treatment Meets Phase III Goals, With 79% Virus-Free at Week 48 Vir Biotechnology NASDAQ: VIR said its combination treatment for chronic hepatitis delta met the primary and key secondary endpoints in the pivotal Phase III ECLIPSE 1 trial, with 79% of treated patients achieving undetectable virus at 48 weeks.
View source ↗ - Newsseekingalpha.com·12d ago·Neutral
Vir Biotechnology: Fairly Valued After Phase 3 Success? Vir Biotechnology remains a Buy after flawless Phase 3 ECLIPSE 1 results and a major new Gilead partnership. VIR's Hepatitis Delta therapy achieved 44% primary endpoint success and 79% undetectable virus rates, with a strong safety profile and no discontinuations. With $991.3 million in cash, a $5.79 per-share cash floor, and funding secured into H2 2028, downside risk is limited.
View source ↗ - Newsseekingalpha.com·13d ago·Positive
Vir Biotechnology, Inc. (VIR) Discusses ECLIPSE 1 Topline Results and Expanded SOLSTICE Data Transcript Vir Biotechnology, Inc. ( VIR ) Discusses ECLIPSE 1 Topline Results and Expanded SOLSTICE Data November 9, 2026 8:30 AM EST Company Participants Kiki Patel - Head of Investor Relations Marianne De Backer - President, CEO & Director Conference Call Participants Cory Kasimov - Evercore ISI Institutional Equities, Research Division Philip Nadeau - TD Cowen, Research Division Alec Stranahan - BofA…
View source ↗ - Newszacks.com·13d ago·Neutral
Wall Street Analysts Predict a 75.59% Upside in Vir Biotechnology (VIR): Here's What You Should Know The mean of analysts' price targets for Vir Biotechnology (VIR) points to a 75.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
View source ↗ - Newsbusinesswire.com·14d ago·Neutral
…Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and Exploratory Finite Treatment Data SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced new, expanded data from the Phase 2 SOLSTICE trial evaluating monthly subcutaneous administration of elebsiran and tobevibart in adults with chronic hepatitis delta (CHD). These data include new analyses presented in oral sessions at the American Association for the Study of Liver Diseases (AASLD) The Liver Mee…
View source ↗ - Newsbusinesswire.com·14d ago·Positive
…point Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced positive topline results from the pivotal Phase 3 ECLIPSE 1 trial evaluating monthly subcutaneous administration of elebsiran and tobevibart in adults with chronic hepatitis delta (CHD). Topline results were presented in an oral session at the American Association for the Study of Liver Diseases (AASLD) The Liv…
View source ↗ - Newsmarketbeat.com·17d ago·Neutral
What Vir Biotechnology (VIR) Said on Its Q3 Earnings Call Vir Biotechnology NASDAQ: VIR expects to report the first phase 3 results for its experimental hepatitis delta treatment in the fourth quarter of 2026, with data from two additional studies due in the first quarter of 2027, executives said on the company's third-quarter earnings call.
View source ↗ - Newsseekingalpha.com·17d ago·Positive
Vir Biotechnology, Inc. (VIR) Q3 2026 Earnings Call Transcript Vir Biotechnology, Inc. (VIR) Q3 2026 Earnings Call Transcript
View source ↗ - Newsseekingalpha.com·26d ago·Neutral
Vir Biotechnology: A Big Pharma Collaboration And 2 Clinical Catalysts This Quarter VIR's PRO-XTEN platform has attracted major pharma collaborations, validating its dual-masked T-cell engager technology for oncology and solid tumors. Near-term catalysts include ECLIPSE program readouts for hepatitis delta (Q4'26/Q1'27) and VIR-5818 oncology data, with positive outcomes likely based on prior results. VIR's competitors in hepatitis delta include GILD and MIRM, but VIR's prior data suggests except…
View source ↗ - Newszacks.com·38d ago·Neutral
Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth? Gilead Sciences expands its oncology pipeline through a Vir Biotechnology deal worth up to $1.74 billion in additional milestones, targeting three novel cancer therapies.
View source ↗ - Newsseekingalpha.com·54d ago·Neutral
Vir Biotechnology: Astellas Deal Highlights The Platform's Value Vir Biotechnology is now a two-engine company, with major pharma partnerships and a fully enrolled hepatitis delta phase 3 program. Gilead's bulevirtide launch is expanding hepatitis delta diagnosis, indirectly benefiting VIR's upcoming ECLIPSE trials targeting bulevirtide non-responders. The Astellas deal validates VIR's PRO-XTEN platform, providing $335 million in upfront and near-term payments and a premium equity investment.
View source ↗
Earnings
Mon, Feb 22(in 3 months)
Consensus estimate $-0.13 per share
Typical surprise -6.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$-0.57 vs $-0.77beat
- Wed, Aug 5$0.47 vs $0.33beat
- Wed, May 6$-0.85 vs $-0.01miss
- Mon, Feb 23$-0.31 vs $-0.42beat
- Wed, Nov 5$-1.17 vs $-0.70miss
- Wed, Aug 6$-0.80 vs $-0.72miss
Estimates and results for VIR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by VIR officers and directors.
- Bought
- —
- Sold
- $21.3m
0 trades
57 trades
- De Verneuil Vaninasold
- De Verneuil Vaninasold
- Napolitano Janetsold
- Sabatini Brentsold
- Sato Vicki Lsold
- De Backer Mariannesold
- Sato Vicki Lsold
- Sabatini Brentsold
43 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in VIR.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
